Thermo Fisher Scientific Inc. $TMO Shares Bought by Security National Bank

Security National Bank grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,095 shares of the medical research company’s stock after buying an additional 2,205 shares during the period. Security National Bank’s holdings in Thermo Fisher Scientific were worth $7,067,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Matrix Asset Advisors Inc. NY raised its position in shares of Thermo Fisher Scientific by 22.7% during the 2nd quarter. Matrix Asset Advisors Inc. NY now owns 27,668 shares of the medical research company’s stock worth $13,872,000 after acquiring an additional 5,121 shares in the last quarter. WealthBridge Investment Counsel Inc. boosted its holdings in Thermo Fisher Scientific by 2.2% in the second quarter. WealthBridge Investment Counsel Inc. now owns 12,852 shares of the medical research company’s stock valued at $6,443,000 after purchasing an additional 275 shares in the last quarter. Tompkins Financial Corp increased its stake in Thermo Fisher Scientific by 2.4% in the second quarter. Tompkins Financial Corp now owns 1,742 shares of the medical research company’s stock valued at $873,000 after purchasing an additional 40 shares during the last quarter. Keudell Morrison Wealth Management raised its holdings in Thermo Fisher Scientific by 5.1% during the second quarter. Keudell Morrison Wealth Management now owns 498 shares of the medical research company’s stock worth $250,000 after purchasing an additional 24 shares in the last quarter. Finally, Firethorn Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 6.3% during the 2nd quarter. Firethorn Wealth Partners LLC now owns 526 shares of the medical research company’s stock worth $264,000 after buying an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $588.17 on Friday. The firm’s fifty day simple moving average is $529.37 and its 200-day simple moving average is $509.58. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The stock has a market capitalization of $217.48 billion, a price-to-earnings ratio of 31.64, a PEG ratio of 2.42 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price target for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Wolfe Research started coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective on the stock. Piper Sandler lifted their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Finally, Evercore set a $570.00 target price on Thermo Fisher Scientific in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares of the company’s stock, valued at $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 52,053 shares of company stock worth $30,643,589 over the last three months. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.